In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi

We determined the in vitro activity of the novel orotomide antifungal, F901318, against 30 Lomentospora prolificans, 20 Scedosporium apiospermum, 7 S. aurantiacum, and 3 S. boydii, isolates in comparison with standard antifungals. Against L. prolificans, F901318 was the most potent compound (MIC90 0...

Full description

Saved in:
Bibliographic Details
Published in:Medical mycology (Oxford) 2018-11, Vol.56 (8), p.1050-1054
Main Authors: Biswas, Chayanika, Law, Derek, Birch, Michael, Halliday, Catriona, Sorrell, Tania C, Rex, John, Slavin, Monica, Chen, Sharon C-A
Format: Article
Language:English
Subjects:
Acetamides - pharmacology
Antifungal Agents - pharmacology
Ascomycota - drug effects
Ascomycota - isolation & purification
Australia
Microbial Sensitivity Tests
Piperazines - pharmacology
Pyrimidines - pharmacology
Pyrroles - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We determined the in vitro activity of the novel orotomide antifungal, F901318, against 30 Lomentospora prolificans, 20 Scedosporium apiospermum, 7 S. aurantiacum, and 3 S. boydii, isolates in comparison with standard antifungals. Against L. prolificans, F901318 was the most potent compound (MIC90 0.25 μg/ml); the geometric mean MIC (0.26 μg/ml) was significantly lower (23-80-fold) than those of itraconazole, voriconazole, posaconazole, and isavuconazole (all P < .001), and amphotericin B (P < .05). F901318 also had good activity against S. apiospermum, S. aurantiacum, and S. boydii, comparable to that of voriconazole and posaconazole but was more active than isavuconazole for all three species.
ISSN:1369-3786
1460-2709
DOI:10.1093/mmy/myx161